Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337308 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 382
- Enrollment target
NCT03337308 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 382 participants.
The verdict
NCT03337308, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 382 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy.
Interventions
- DRUG Placebos
- DRUG Bempedoic Acid
- DRUG Ezetimibe
- COMBINATION_PRODUCT Bempedoic Acid + Ezetimibe Fixed-Dose Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2018-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337308
The ClinicalTrials.gov registry entry for NCT03337308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebos is the first listed.
NCT03337308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03337308 about?
NCT03337308 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy". The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy.
What is the current status of trial NCT03337308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 382 participants. The study started on 2017-10-23. Estimated completion is 2018-07-18.
What interventions are being tested in trial NCT03337308?
The interventions under investigation include: Placebos (DRUG), Bempedoic Acid (DRUG), Ezetimibe (DRUG), Bempedoic Acid + Ezetimibe Fixed-Dose Combination (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03337308?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.